Department of Orthopedic Surgery, Mie University School of Medicine, 2-174 Edobashi, 514-8507, Tsu City, Mie, Japan.
Department of Pharmacology, Faculty of Medicine, Shimane University, Izumo, Shimane, Japan.
BMC Cancer. 2022 Oct 18;22(1):1075. doi: 10.1186/s12885-022-10106-4.
Coagulation and fibrinolysis are distinct processes that are highly correlated. Cells control coagulation and fibrinolysis by expression of tissue factor and urokinase-type plasminogen activator receptor on their surface. Tumor cells express these proteins, adjust their microenvironment and induce tumor exacerbation. We hypothesized that the expression of plasma markers for coagulation and fibrinolysis in patients with soft tissue sarcomas (STSs) was dependent on the level of tumor malignancy. To elucidate which markers are predictive of recurrence, metastasis and prognosis, coagulation or fibrinolysis, we analyzed the correlation between plasma levels of thrombin-antithrombin III complex (TAT), soluble fibrin (SF), plasmin-α2 plasmin inhibitor complex (PIC), D-dimer (DD) and clinical parameters in patients with STSs.
TAT, SF, PIC or DD were measured in pre-treatment blood samples from 64 patients with primary STSs and analyzed with clinicopathological parameters, and 5-year recurrence free survival (RFS), 5-year metastasis free survival (MFS) and 5-year overall survival (OS) were evaluated.
The metastasis group had significantly higher DD (p = 0.0394), PIC (p = 0.00532) and SF (p = 0.00249) concentrations than the group without metastasis. The group that died of disease showed significantly higher DD (p = 0.00105), PIC (p = 0.000542), SF (p = 0.000126) and TAT (p = 0.0373) than surviving patients. By dividing the patients into low and high groups, the group with high DD, PIC, SF and TAT showed significantly lower 5-year MFS and 5-year OS than the corresponding low group. Furthermore, in multivariate COX proportional hazard analysis of continuous variables for 5-year MFS, only PIC was found to be a significant factor (HR: 2.14).
Fibrinolysis was better than coagulation at reflecting the disease condition of patients with STS. Notably, PIC levels ≥ 1.1 can not only predict the risk of metastasis and poor prognosis, but also increasing PIC levels correspond to further increases in risks of metastasis and poor prognosis.
凝血和纤溶是两个相互关联的独特过程。细胞通过在其表面表达组织因子和尿激酶型纤溶酶原激活物受体来控制凝血和纤溶。肿瘤细胞表达这些蛋白质,调节其微环境并诱导肿瘤恶化。我们假设软组织肉瘤(STS)患者血浆中凝血和纤溶标志物的表达取决于肿瘤恶性程度。为了阐明哪些标志物可预测复发、转移和预后,是凝血或纤溶,我们分析了 STS 患者血浆中凝血酶-抗凝血酶 III 复合物(TAT)、可溶性纤维蛋白(SF)、纤溶酶-α2 纤溶酶抑制剂复合物(PIC)、D-二聚体(DD)的水平与临床参数之间的相关性。
检测了 64 例原发性 STS 患者治疗前血液样本中的 TAT、SF、PIC 或 DD,并与临床病理参数进行分析,评估 5 年无复发生存率(RFS)、5 年无转移生存率(MFS)和 5 年总生存率(OS)。
转移组的 DD(p = 0.0394)、PIC(p = 0.00532)和 SF(p = 0.00249)浓度明显高于无转移组。死于疾病的患者组的 DD(p = 0.00105)、PIC(p = 0.000542)、SF(p = 0.000126)和 TAT(p = 0.0373)浓度明显高于存活患者。将患者分为低和高两组,DD、PIC、SF 和 TAT 高的患者组 5 年 MFS 和 5 年 OS 明显低于相应的低组。此外,在 5 年 MFS 的连续变量多变量 COX 比例风险分析中,只有 PIC 被发现是一个显著因素(HR:2.14)。
纤溶比凝血更能反映 STS 患者的病情。值得注意的是,PIC 水平≥1.1 不仅可以预测转移和预后不良的风险,而且随着 PIC 水平的升高,转移和预后不良的风险也会进一步增加。